Deferasirox售价多少一盒？

(Deferasirox, Enriga) was developed by Novartis and is currently the only oral iron chelator. Iron chelators are currently the mainstream treatment for iron removal. Among them, Deferasirox (Deferasirox, Enrig) ​​is easy to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment. So, how much does a box of Deferasirox cost?

There are currently two versions of Desirox available in India. Novartis from Switzerland imports it from Enrig in India. The specification is 400mg*30 tablets/box and the price is about $700. The specification of Enriga produced by Indian pharmaceutical factory is 500*30 tablets/box, and the price is about 500$. Due to the fluctuation of exchange rate, the price will be different. Please consult the medical companion tour for the specific price! 

Desirox is already on the market in China, and patients can purchase it at major hospitals or pharmacies in the country with a prescription issued by a doctor! Patients can also obtain Indian Desirox drugs through domestic professional German overseas medical service organizations (such as Medical Companion Travel), which are guaranteed to be genuine.

Deferasirox (Deferasirox, Enrig) is more convenient and has higher patient compliance. EPIC is currently the largest prospective, open, single-group, global multi-center clinical study designed for patients with iron overload. A total of 341 MDS patients were enrolled, and it could reduce serum ferritin by an average of 372 μg/L in 3 months.

More importantly, the benefits of iron removal therapy are not only reflected in the reduction of ferritin levels, but can also improve the patient's hematological response, stabilize and reverse the patient's liver fibrosis, improve the heart's ejection fraction, and prevent the occurrence of important cardiac events such as heart failure and arrhythmia.

my country's data also supports the above conclusion. The results of a single-arm, multi-center, prospective clinical study enrolling 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of Deferasirox (Deferasirox, Enrig) ​​in reducing patients' ferritin levels. A prospective, observational study in my country that used liver, pancreas, and heart as monitoring indicators confirmed that Deferasirox (Deferasirox, Enrig) ​​can improve organ function in patients with iron overload.

The results of the TELESTO study released at ASH2018 also proved that Deferasirox (Deferasirox, Enrig) continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

The above is the price content of (Dedeferasirox, Enrego), I hope it can help you!